- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 211/40 - Atomes d'oxygène
Détention brevets de la classe C07D 211/40
Brevets de cette classe: 114
Historique des publications depuis 10 ans
|
8
|
4
|
8
|
6
|
7
|
5
|
5
|
6
|
9
|
3
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| FMC Corporation | 838 |
5 |
| Theravance Biopharma R&D IP, LLC | 456 |
5 |
| ChemoCentryx, Inc. | 383 |
4 |
| AstraZeneca AB | 2886 |
3 |
| Amgen Inc. | 4108 |
3 |
| Bristol-myers Squibb Company | 4849 |
2 |
| F. Hoffmann-La Roche AG | 7948 |
2 |
| Board of Regents, The University of Texas System | 5869 |
2 |
| ABAC Therapeutics S.L. | 7 |
2 |
| Athenex, Inc. | 26 |
2 |
| Neurocrine Biosciences, Inc. | 430 |
2 |
| Nippon Soda Co., Ltd. | 894 |
2 |
| Sirna Therapeutics, Inc. | 110 |
2 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2874 |
2 |
| Idorsia Pharmaceuticals Ltd. | 357 |
2 |
| Shanghai Meizer Pharmaceuticals Co., Ltd. | 14 |
2 |
| Vividion Therapeutics, Inc. | 37 |
2 |
| ReNAgade Therapeutics Management Inc. | 43 |
2 |
| Hong Kong King-friend Industrial Company Ltd. | 40 |
2 |
| Hoffmann-La Roche Inc. | 3478 |
1 |
| Autres propriétaires | 65 |